<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186221</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-LVR10202019</org_study_id>
    <nct_id>NCT04186221</nct_id>
  </id_info>
  <brief_title>OCS Liver PROTECT Continued Access Protocol</brief_title>
  <official_title>Continued Access Protocol To Evaluate the Effectiveness of the Portable Organ Care System (OCS) Liver for Preserving and Assessing Donor Livers for Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve&#xD;
      and assess donor livers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single arm, continued access protocol to evaluate the effectiveness of the OCS&#xD;
      Liver System to preserve and assess donor livers having one or more of the following&#xD;
      characteristics:&#xD;
&#xD;
        1. Donor age equal to or greater than 40 years old, or&#xD;
&#xD;
        2. Expected cross clamp time of 6 hours or greater, or&#xD;
&#xD;
        3. Donor after circulatory death (DCD) with age less than or equal to 55 years; or&#xD;
&#xD;
        4. Steatotic lever &gt;0% and less than or equal to 40% at time of retrieval, based on&#xD;
           pre-retrieval histology)&#xD;
&#xD;
      A maximum of 21 sites will enroll up to 184 transplanted liver recipients. The primary&#xD;
      effectiveness endpoint will be the incidence of Early Allograft Dysfunction (EAD) or primary&#xD;
      non-function.&#xD;
&#xD;
      All recipients will be followed for 24 months from the date of transplantation (some of which&#xD;
      will be post-market).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">February 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-arm, continued access protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of EAD or primary non-function</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of early allograft dysfunction or primary non-function of donor liver</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCS donor liver assessment during perfusion</measure>
    <time_frame>During OCS perfusion, on average 4 hours</time_frame>
    <description>Collection of liver perfusion parameters while on OCS device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at Day 30 post-transplantation</measure>
    <time_frame>30 days</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at initial hospital discharge post liver transplantation</measure>
    <time_frame>30 days</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of initial post-transplant ICU stay</measure>
    <time_frame>ICU days, on average 5 days</time_frame>
    <description>ICU stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of initial post-transplant hospital stay</measure>
    <time_frame>Hospital days, on average 10 days</time_frame>
    <description>Hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Evidence of ischemic biliary complications diagnosed at 6 and 12 months post transplant</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Ischemic biliary complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Extend to reperfusion syndrome as assessed based on the rate of decrease of lactate</measure>
    <time_frame>anhepatic phase, 30-40 minutes after hepatic artery and portal vein reperfusion, 90-120 minutes after reperfusion of the transplanted liver</time_frame>
    <description>Reperfusion syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathology sample score for liver samples</measure>
    <time_frame>Procedure (Pre-retrieval, Post-OCS preservation (on average, 4 hours), post reperfusion 90-120 min after reperfusion and prior to abdominal closure)</time_frame>
    <description>Pathology sample scoring</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Liver System</intervention_name>
    <description>OCS Liver System for preserving and assessing donor livers for transplantation</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:&#xD;
&#xD;
          -  Registered primary liver transplant candidate, male or female&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed (1) written informed consent document and (2) authorization to use and disclose&#xD;
             protected health information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute, fulminant liver failure&#xD;
&#xD;
          -  Prior solid organ or bone marrow transplant&#xD;
&#xD;
          -  Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic&#xD;
             serum creatinine of &gt; 3 mg/dl for &gt; 2 weeks and/or requiring hemodialysis&#xD;
&#xD;
          -  Multi-organ transplant&#xD;
&#xD;
          -  Ventilator dependent&#xD;
&#xD;
          -  Dependent on &gt; 1 IV inotrope to maintain hemodynamics&#xD;
&#xD;
        Donor Inclusion Criteria&#xD;
&#xD;
          -  Donor age ≥ 40 years, or&#xD;
&#xD;
          -  Expected cross-clamp time ≥ 6 hours, or&#xD;
&#xD;
          -  Donor after circulatory death (DCD) with age ≤ 55 years, or&#xD;
&#xD;
          -  Steatotic liver &gt; 0% and ≤ 40% macrosteatosis at time of retrieval&#xD;
&#xD;
        Donor Exclusion Criteria&#xD;
&#xD;
          -  Living donors&#xD;
&#xD;
          -  Liver intended for split transplants&#xD;
&#xD;
          -  Positive serology (HIV, Hepatitis B surface antigen &amp; Hepatitis C)&#xD;
&#xD;
          -  Presence of moderate or severe traumatic liver injury, or anatomical liver&#xD;
             abnormalities that would compromise ex-vivo perfusion of the donor liver (i.e.,&#xD;
             accessory blood vessels or other anatomy that require surgical repair) and livers with&#xD;
             active bleeding (e.g., hematomas)&#xD;
&#xD;
          -  Donor livers with macrosteatosis of &gt; 40% based on retrieval biopsy readout.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elbetanony, MD</last_name>
    <role>Study Director</role>
    <affiliation>TransMedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Transplantation</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

